JAZZ - Jazz Pharmaceuticals plc Price-to-Projected Revenue Ratio

Jazz Pharmaceuticals PLC (JAZZ) - corporate logo

Patent protection and strict FDA regulations create a powerful barrier to generics, which justifies the current forward P/S ratio for Jazz Pharmaceuticals (JAZZ). 0.40 serves as the current level of this metric. The business relies on a closed neurobiological ecosystem with unique sleep therapies. Success is driven by elite scientists attracted by comfortable working conditions and stable funding for their research.

Jazz Pharmaceuticals PLC - JAZZ Projected Price to Revenue (period 07/04/2022 - 11/14/2026)

Analytical breakdowns for Jazz Pharmaceuticals (JAZZ)

- market price and analyst price targets:
Price Chart Jazz Pharma|JAZZ - Price Target Chart
- market capitalization statistics:
Market Value Jazz Pharmaceuticals Corp|JAZZ - Total Enterprise Value
- book value of equity indicators:
Book Value per Share Jazz Pharmaceuticals|JAZZ - Book Value of Business|Market Cap to Net Assets Ratio jazzpharma.com|JAZZ - Company Assets
- debt and liquidity data:
Debt to Equity Jazz Pharmaceuticals|JAZZ - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital jazzpharma.com|JAZZ - Company Aggregate Debts|Debt to Book Value Jazz Pharmaceuticals|JAZZ - Long-Term Liabilities|Company Current Liabilities Jazz Pharmaceuticals|Quick Liquidity Indicator jazzpharma.com
- financial results and valuation multiples details:
JAZZ - Final Profit|Expected Profit Jazz Pharmaceuticals|JAZZ - Market Cap to Net Income|Forward P/E Multiple Jazz Pharmaceuticals|JAZZ - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Jazz Pharmaceuticals|JAZZ - Operating profit EBITDA|Earnings per share for the last twelve months Jazz Pharmaceuticals|JAZZ - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months jazzpharma.com|JAZZ - Net earnings per share growth this year|Earnings growth forecast for next year Jazz Pharmaceuticals
- revenue and sales proceeds data:
JAZZ - Revenue and Sales Volume|Projected Sales Volume Jazz Pharmaceuticals Corp|JAZZ - Market Cap to Revenue|Forward P/S Multiple Jazz Pharmaceuticals Corp
Fundamental company analysis:Jazz Pharmaceuticals plc (JAZZ)
Original product of Jazz Pharmaceuticals Corp

Steady cash flow from therapies for rare neurological disorders creates a solid foundation for the capitalization of Jazz Pharmaceuticals (JAZZ). The ratio of market value to expected revenue, represented by the issuer's forward P/S, measures the premium for future sales growth, allowing investors to determine the extent of overpayment for a business model characterized by high consumption inertia and protection against generics.

Direct competitors

Price-to-Projected Revenue Ratio Cytokinetics Inc CYTK|PTC Bio - Price-to-Projected Revenue Ratio|SRRK - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Centessa Pharmaceuticals|DYN (Dyne Corp) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Edgewise Pharma EWTX|Forward Price-to-Revenue Multiple RAPP|Market Cap to Future Revenue Ratio Alumis Corp ALMS|Forward Price-to-Revenue Multiple ZVRA (Kempharm)|Forward Price-to-Revenue Multiple contineum-tx.com CTNM|Forward P/S Multiple LRMR (larimartx.com)|Forward P/S Multiple Capricor Therapeutics CAPR|TRDA: Forward Price-to-Revenue Multiple|PTHS - Forward P/S Multiple|MNOV: Forward P/S Multiple|Market Cap to Projected Revenue SER|BTAI (BioXcel Therapeutics Inc) - Forward P/S Multiple|ProMIS Neurosciences, Inc. (PMN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple APUS|Price-to-Projected Revenue Ratio AEON (AEON Biopharma, Inc.)|Forward P/S Multiple NLSP (NLS Pharmaceutics Ltd.)|Market Cap to Expected Sales Ratio Bionomics Ltd (BNOX)|HUGE - Price-to-Projected Revenue Ratio|Forward Price to Sales RETA (Reata Pharmaceuticals, Inc.)